SCHEMBL19965854

SCHEMBL19965854

Cc1ccc2c(n1)sc1c2nc(CCc2nc3c4cccnc4sc3n2C)n1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 4/20 0.40
PDE10A Q9Y233 12/20 0.38
NPC1 O15118 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CDC7 O00311 1/20 0.34
CLK1 P49759 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
IKBKB O14920 2/20 0.33
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
THRB P10828 1/20 0.32
CHUK O15111 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10309357 0.91 PDE10A (0.43) LIMK1PDE10AALDH1A1HPGDCDC7
SCHEMBL10309342 0.77 PDE10A (0.53) PDE10A
SCHEMBL22373899 0.75 LIMK1 (0.46) LIMK1NPC1KDM4EALDH1A1USP2
SCHEMBL19291909 0.74 LIMK1 (0.34) LIMK1PDE10ACDC7CLK1DBF4
SCHEMBL18634485 0.73 PDE10A (0.33) LIMK1PDE10A
SCHEMBL22373964 0.71 MAPT (0.48) LIMK1NPC1KDM4EALDH1A1USP2
SCHEMBL22373808 0.71 LIMK1 (0.50) LIMK1NPC1KDM4EALDH1A1USP2
SCHEMBL10309420 0.70 CYP2A6 (0.43) LIMK1NPC1KDM4EALDH1A1MAPT
SCHEMBL10309421 0.66 LIMK1 (0.43) LIMK1NPC1ALDH1A1HPGDCDC7
SCHEMBL10345238 0.62 PDE10A (0.72) PDE10AKDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2020-02-25 US disclosed
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN LIMK1 1839/4885PDE10A 2086/4885NPC1 458/4885
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors PDE3A, PDE2A, PDE5A LIMK1 3733/4885PDE10A 5/4885NPC1 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.